nct_id: NCT06395103
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-05-01'
study_start_date: '2024-08-16'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Biological: Zilovertamab vedotin'
long_title: 'LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety
  and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With
  Hematologic Malignancies or Solid Tumors'
last_updated: '2025-11-14'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Merck Sharp & Dohme LLC
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 90
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'The main inclusion and exclusion criteria include but are not limited to the following:'
- 'Inclusion Criteria:'
- '* For hematological malignancies: Confirmed diagnosis of B-precursor B-ALL or DLBCL/Burkitt
  lymphoma according to World Health Organization (WHO) classification of neoplasms
  of the lymphoid tissues.'
- '* For solid tumor malignancies: Histologically confirmed diagnosis of neuroblastoma
  or Ewing sarcoma.'
- 'Exclude - Exclusion Criteria:'
- Exclude - * History of solid organ transplant.
- Exclude - * Clinically significant (ie, active) cardiovascular disease.
- Exclude - * Known history of liver cirrhosis.
- Exclude - * Ongoing Grade \>1 peripheral neuropathy.
- Exclude - * Demyelinating form of Charcot-Marie-Tooth disease.
- Exclude - * Diagnosed with Down syndrome.
- Exclude - * Ongoing graft-versus-host disease (GVHD) of any grade or receiving systemic
  GVHD treatment or prophylaxis.
- Exclude - * History of human immunodeficiency virus (HIV) infection.
- Exclude - * Contraindication or hypersensitivity to any of the study intervention
  components.
- Exclude - * Received prior radiotherapy within 4 weeks of start of study intervention.
  Participants must have recovered from all radiation-related toxicities.
- Exclude - * Ongoing, chronic corticosteroid therapy (exceeding 10 mg daily of prednisone
  equivalent). Prednisone equivalent dosing must have been stable for at least 4 weeks
  before Cycle 1 Day 1 (C1D1).
- Exclude - * Received a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 7 days
  or a strong CYP3A4 inducer within 14 days before the start of study intervention
  or expected requirement for chronic use of a strong CYP3A4 inhibitor or inducer
  during the study intervention period and for 30 days after the last dose of study
  intervention
- Exclude - * Received prior systemic anticancer therapy including investigational
  agents within 4 weeks before the first dose of study intervention (except for prophylactic
  intrathecal chemotherapy and/or cytoreductive therapy with steroids/hydroxyurea.
- Exclude - * Received a live or live-attenuated vaccine within 30 days before the
  first dose of study intervention. Administration of killed vaccines is allowed.
- Exclude - * Has received an investigational agent or has used an investigational
  device within 4 weeks prior to study intervention administration.
- Exclude - * Known additional malignancy that is progressing or has required active
  treatment within the past 1 year.
- Exclude - * Active infection requiring systemic therapy.
- Exclude - * Known history of Hepatitis B or known active Hepatitis C virus infection.
- Exclude - * Participants who have not adequately recovered from major surgery or
  have ongoing surgical complications.
short_title: 'Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants
  With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)'
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Merck Sharp & Dohme LLC
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: Substudy 01A is part of a platform study. The purpose of this study is to
  assess the efficacy and safety of zilovertamab vedotin in pediatric participants
  with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse
  large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric
  and young adult participants with Ewing sarcoma.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Zilovertamab vedotin
      arm_internal_id: 0
      arm_description: Participants receive escalating doses of zilovertamab vedotin
        via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: Zilovertamab vedotin'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Neuroblastoma
        - clinical:
            oncotree_primary_diagnosis: Lymphoid Neoplasm
        - clinical:
            oncotree_primary_diagnosis: Ewing Sarcoma
      - clinical: {}
